MARC details
| 000 -LEADER |
|---|
| fixed length control field |
09035nam a22003977i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20200916114421.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150222s2014 enka|||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0857111388 (pbk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780857111388 (pbk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0857111566 (Paper) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780857111562 (Paper) |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-NcFUE |
| Description conventions |
rda |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Edition number |
23 |
| Classification number |
615.1 |
| Item number |
B |
| 110 2# - MAIN ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Joint Formulary Committee (Great Britain) |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
British national formulary |
| Number of part/section of a work |
68, |
| Name of part/section of a work |
September 2014 - March 2015. |
| 246 1# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
BNF 68 |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
68th edition. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
London : |
| Name of publisher, distributor, etc |
BMJ Group ; |
| -- |
Pharmaceutical Press, |
| Date of publication, distribution, etc |
2014. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xviii, 1148 pages : |
| Other physical details |
color illustrations ; |
| Dimensions |
22 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Include index. |
| 500 ## - GENERAL NOTE |
|---|
| General note |
pharmacy bookfair2015 |
| 500 ## - GENERAL NOTE |
|---|
| General note |
"published under the authority of a Joint Formulary Committee"-pref. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Cover -- Preface -- Contents -- General Information -- Acknowledgements -- BNF Staff -- Joint Formulary Committee 2011-2012 -- Dental Advisory Group 2011-2012 -- Nurses Prescribers' Advisory Group 2011-2012 -- How the BNF is constructed -- How to use the BNF -- Changes for this edition -- Guidance on prescribing -- General guidance -- Prescription writing -- Emergency supply of medicines -- Controlled Drugs and drug dependence -- Adverse reactions to drugs -- Prescribing for children -- Prescribing in hepatic impairment -- Prescribing in renal impairment -- Prescribing in pregnancy -- Prescribing in breast-feeding -- Prescribing in palliative care -- Prescribing for the elderly -- Prescribing in dental practice -- Drugs and sport -- Emergency treatment of poisoning -- 1 Gastro-intestinal system -- 1.1 Dyspepsia and gastro-oesophageal reflux disease -- 1.2 Antispasmodics and other drugs altering gut motility -- 1.3 Antisecretory drugs and mucosal protectants -- 1.4 Acute diarrhoea -- 1.5 Chronic bowel disorders -- 1.6 Laxatives -- 1.7 Local preparations for anal and rectal disorders -- 1.8 Stoma care -- 1.9 Drugs affecting intestinal secretions -- 2 Cardiovascular system -- 2.1 Positive inotropic drugs -- 2.2 Diuretics -- 2.3 Anti-arrhythmic drugs -- 2.4 Beta-adrenoceptor blocking drugs -- 2.5 Hypertension and heart failure -- 2.6 Nitrates, calcium-channel blockers, and other antianginal drugs -- 2.7 Sympathomimetics -- 2.8 Anticoagulants and protamine -- 2.9 Antiplatelet drugs -- 2.10 Stable angina, acute coronary syndromes, and fibrinolysis -- 2.11 Antifibrinolytic drugs and haemostatics -- 2.12 Lipid-regulating drugs -- 2.13 Local sclerosants -- 3 Respiratory system -- 3.1 Bronchodilators -- 3.2 Corticosteroids -- 3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors.<br/>3.4 Antihistamines, hyposensitisation, and allergic emergencies -- 3.5 Respiratory stimulants and pulmonar surfactants -- 3.6 Oxygen -- 3.7 Mucolytics -- 3.8 Aromatic inhalations -- 3.9 Cough preparations -- 3.10 Systemic nasal decongestants -- 4 Central nervous system -- 4.1 Hypnotics and anxiolytics -- 4.2 Drugs used in psychoses and related disorders -- 4.3 Antidepressant drugs -- 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder -- 4.5 Drugs used in the treatment of obesity -- 4.6 Drugs used in nausea and vertigo -- 4.7 Analgesics -- 4.8 Antiepileptic drugs -- 4.9 Drugs used in parkinsonism and related disorders -- 4.10 Drugs used in substance dependence -- 4.11 Drugs for dementia -- 5 Infections -- 5.1 Antibacterial drugs -- 5.2 Antifungal drugs -- 5.3 Antiviral drugs -- 5.4 Antiprotozoal drugs -- 5.5 Anthelmintics -- 6 Endocrine system -- 6.1 Drugs used in diabetes -- 6.2 Thyroid and antithyroid drugs -- 6.3 Corticosteroids -- 6.4 Sex hormones -- 6.5 Hypothalamic and pituitary hormones and anti-oestrogens -- 6.6 Drugs affecting bone metabolism -- 6.7 Other endocrine drugs -- 7 Obstetrics, gynaecology, and urinary-tract disorders -- 7.1 Drugs used in obstetrics -- 7.2 Treatment of vaginal and vulval conditions -- 7.3 Contraceptives -- 7.4 Drugs for genito-urinary disorders -- 8 Malignant disease and immunosuppression -- 8.1 Cytotoxic drugs -- 8.2 Drugs affecting the immune response -- 8.3 Sex hormones and hormone antagonists in malignant disease -- 9 Nutrition and blood -- 9.1 Anaemias and some other blood disorders -- 9.2 Fluids and electrolytes -- 9.3 Intravenous nutrition -- 9.4 Oral nutrition -- 9.5 Minerals -- 9.6 Vitamins -- 9.7 Bitters and tonics -- 9.8 Metabolic disorders -- 10 Musculoskeletal and joint diseases -- 10.1 Drugs used in rheumatic diseases and gout -- 10.2 Drugs used in neuromuscular disorders.<br/>10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief -- 11 Eye -- 11.1 Administration of drugs to the eye -- 11.2 Control of microbial contamination -- 11.3 Anti-infective eye preparations -- 11.4 Corticosteroids and other anti-inflammatory preparations -- 11.5 Mydriatics and cycloplegics -- 11.6 Treatment of glaucoma -- 11.7 Local anaesthetics -- 11.8 Miscellaneous ophthalmic preparations -- 11.9 Contact lenses -- 12 Ear, nose, and oropharynx -- 12.1 Drugs acting on the ear -- 12.2 Drugs acting on the nose -- 12.3 Drugs acting on the oropharynx -- 13 Skin -- 13.1 Management of skin conditions -- 13.2 Emollient and barrier preparations -- 13.3 Topical localan aesthetics and antipruritics -- 13.4 Topical corticosteroids -- 13.5 Preparations for eczema and psoriasis -- 13.6 Acne and rosacea -- 13.7 Preparations for warts and calluses -- 13.8 Sunscreens and camouflagers -- 13.9 Shampoos and other preparations for scalp and hair conditions -- 13.10 Anti-infective skin preparations -- 13.11 Skin cleansers, antiseptics, and desloughing agents -- 13.12 Antiperspirants -- 13.13 Topical circulatory preparations -- 14 Immunological products and vaccines -- 14.1 Active immunity -- 14.2 Passive immunity -- 14.3 Storage and use -- 14.4 Vaccines and antisera -- 14.5 Immunoglobulins -- 14.6 International travel -- 15 Anaesthesia -- 15.1 General anaesthesia -- 15.2 Local anaesthesia -- Appendix 1 Interactions -- Appendix 2 Borderline substances -- A2.1 Enteral feeds (non-disease specific) -- A2.2 Nutritional supplements (non-disease specific) -- A2.3 Specialised formulas -- A2.4 Feed supplements -- A2.5 Feed additives -- A2.6 Foods for special diets -- A2.7 Nutritional supplements for metabolic diseases -- Appendix 3 Cautionary and advisory labels for dispensed medicines -- Appendix 4 Intravenous additives.<br/>Appendix 5 Wound management products and elasticated garments -- A5.1 Basic wound contact dressings -- A5.2 Advanced wound dressings -- A5.3 Antimicrobial dressings -- A5.4 Specialised dressings -- A5.5 Adjunct dressings and appliances -- A5.6 Complex adjunct therapies -- A5.7 Wound care accessories -- A5.8 Bandages -- A5.9 Compression hosiery and garments -- Dental Practitioners' Formulary -- Nurse Prescribers' Formulary -- Non-medical prescribing -- Index of manufacturers -- Special-order Manufacturers -- Index -- Yellow Card -- Cardiovascular Risk Prediction Charts -- Adult Advanced Life Support Algorithm -- Medical emergencies in thecommunity -- General reference -- Approximate conversions and units -- Prescribing for children -- Recommended wording of cautionary and advisory labels -- Abbreviations and symbols -- Latin abbreviations -- E numbers. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Nobody working in healthcare can afford to be without the latest<br/>edition of the British National Formulary. Compiled with the<br/>advice of clinical experts and continually updated to reflect the<br/>latest evidence from all credible sources worldwide, this essential<br/>reference provides up-to-date guidance on prescribing,<br/>dispensing, administering, and monitoring medicines. Not only<br/>does the BNF include the widely accepted framework for the drug<br/>management of common diseases, it also includes details of<br/>medicines prescribed in the UK, with special reference to their<br/>uses, cautions, contraindications, side-effects, dosage and relative<br/>costs. This allows treatment to be tailored to the individual needs<br/>of each patient. The BNF is updated in print every six months by<br/>an expert team of pharmacists, with guidance and validation from<br/>a network of leading clinicians, overseen by a Joint Formulary<br/>Committee with representatives from all spheres of clinical<br/>practice. The BNF reflects current best practice as well as legal<br/>and professional guidelines relating to the use of medicines. As a<br/>result it is used widely as a touchstone reference, and cited in<br/>Parliaments and courts as a source of authority. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacopoeias |
| Geographic subdivision |
Great Britain. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drugs |
| General subdivision |
Prescribing |
| Geographic subdivision |
Great Britain |
| Form subdivision |
Handbooks, manuals, etc. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine |
| Geographic subdivision |
Great Britain |
| Form subdivision |
Handbooks, manuals, etc. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine |
| Form subdivision |
Formulae, receipts, prescriptions. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
British Medical Association. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Royal Pharmaceutical Society. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |